+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.

Age: 18Years +All GendersPhase 3
301 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ML-007C-MA in adults aged 55 to 90 years who experience hallucinations and delusions associated with Alzheimers Disease Psychosis ADP. This Phase 2, randomized, double-blind, placebo-controlled study aims to compare ML-007C-MA with a placebo to see how well it treats these symptoms, as measured by the Neuropsychiatric Inventory-Clinician NPI-C Hallucinations and Delusions score. Participants will receive either ML-007C-MA, dosed as 1051.5 mg twice daily or 2103 mg twice daily, or placebo tablets. The study uses a parallel design and the treatment period lasts 7 weeks. The main focus is to observe changes from the start to the end of treatment in hallucinations and delusions scores, along with other secondary measures related to agitation, aggression, and clinical global impressions. During the study, participants will be closely monitored through assessments including the NPI-C HD score at baseline and after 7 weeks of treatment. Additional evaluations include clinical global impressions and agitationaggression scores for some participants. The study involves regular check-ins to track symptom changes and adherence to the treatment. Participants remain under careful medical observation throughout, with the study concluding in December 2027.

Age: 55Years - 90YearsAll GendersPhase 2
62 locations
R

Actively Recruiting

Researchers are evaluating whether adding zilovertamab vedotin to the standard treatment can help people with previously untreated diffuse large B-cell lymphoma DLBCL live longer without their cancer growing or spreading. This phase 3 randomized study compares the combination of zilovertamab vedotin with rituximab plus cyclophosphamide, doxorubicin, and prednisone R-CHP against the standard treatment of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP. Participants receive treatments in 21-day cycles for up to six cycles approximately four months. One group receives zilovertamab vedotin with rituximab or its biosimilar, cyclophosphamide, doxorubicin, and prednisone or similar steroids, while the other group receives rituximab or its biosimilar, cyclophosphamide, doxorubicin, vincristine, and prednisone or similar steroids. Both groups may receive up to two additional cycles of rituximab or its biosimilar as decided by the investigator. During the study, participants will have regular assessments including imaging scans and heart function tests to monitor their health and response to treatment. Researchers will measure how long participants live without disease progression, overall survival, response rates, and quality of life up to several years. Safety is monitored by tracking adverse events and treatment discontinuations. The study lasts several years, with primary outcome assessments up to about 50 months and overall survival monitored up to approximately 74 months.

Age: 18Years +All GendersPhase 3
285 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are studying the Caris Biorepository, a project designed to collect and store high-quality biological specimens and related clinical data to support research aimed at advancing precision medicine and improving patient care. This observational study focuses on gathering samples and information from various sources, including healthy individuals and cancer patients, to help understand disease treatments and clinical outcomes. The biorepository includes samples from different donor groups, such as those with no disease, treatment-nave patients with new solid tumors, individuals at higher risk for cancer, patients with advanced cancer, and those with a history of cancer but no active disease. The project aims to maintain molecular integrity and clinical relevance of these specimens while providing access to researchers and collaborators for drug development, clinical trials, and healthcare policy enhancements. Participants provide informed consent and contribute biological samples and clinical data that are securely stored and shared for research purposes. The study measures include ensuring specimen quality and relevance over 35 years and facilitating specimen release for testing. Laboratory testing will be conducted throughout the study duration. The project supports long-term research collaboration and aims to impact patient outcomes and treatment practices over time.

Age: 18Years +All Genders
38 locations
R

Actively Recruiting

The trial investigates the effectiveness of NeoThelium FT combined with standard care compared to standard care alone in treating diabetic foot ulcers. This open-label randomized controlled crossover study is conducted across multiple medical centers and aims to evaluate wound healing outcomes and pain relief in patients with chronic diabetic foot ulcers. The study includes adult participants with diabetes mellitus who have ulcers that meet specific criteria. Participants are randomly assigned to receive either standard care alone or standard care plus NeoThelium FT, a wound covering made from human placental tissue. Those initially receiving standard care who do not achieve complete wound closure by about 84 days may cross over to the NeoThelium FT treatment arm, receiving weekly applications for up to 12 visits. All participants undergo a two-week screening before randomization. During the study, participants have regular assessments including wound measurements and pain evaluations at specific intervals over 12 weeks. Researchers monitor the percentage of ulcers achieving full closure, wound area reduction, time to closure, and pain levels. The trial supports gathering data for insurance reimbursement decisions and tracks participants through follow-up visits according to the study schedule.

Age: 18Years +All GendersPhase Not Applicable
8 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of Hyalomatrix, a hyaluronic acid-based wound dressing, combined with standard of care SOC compared to SOC alone in treating venous leg ulcers. This open-label, randomized controlled trial includes adults diagnosed with venous leg ulcers or venous insufficiency with lower extremity wounds, aiming to assess wound healing over a 12-week period and support insurance reimbursement decisions. Participants will be randomly assigned to either receive SOC alone, which includes wound cleansing, sharps debridement, moisture-balancing dressings, and compression therapy, or SOC plus weekly Hyalomatrix applications. Subjects in the SOC group who do not achieve complete wound closure by about 84 days post-randomization and meet eligibility criteria may cross over to receive Hyalomatrix treatment for up to 12 weeks while continuing follow-up visits. During the study, participants will attend treatment visits where wound healing progress, pain levels, and wound area reduction are monitored regularly. Researchers will measure complete wound closure within 1 to 12 weeks as the primary outcome, along with weekly percentage area reduction and pain assessments for up to 14 weeks. The study emphasizes ongoing safety and efficacy monitoring throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase Not Applicable
4 locations
R

Actively Recruiting

This research registry collects prospective information on patients managing chronic pain caused by knee osteoarthritis OA or optimizing pain treatment for knee replacement surgery due to knee OA. It aims to gather data on various pain therapies used for OA, including cryo nerve block, radiofrequency ablation RFA, injections like corticosteroids, viscosupplementation, opioids, and other medications such as non-steroidal anti-inflammatory drugs NSAIDs. Participants receive different pain management treatments as part of their care for knee OA, which may include procedures like nerve blocks or injections, or undergo knee arthroplasty if needed. The registry monitors these therapies and treatments over time without assigning specific interventions since it is observational. Throughout the study, participants provide information through questionnaires and medication logs to track pain levels using scales like the Numeric Rating Scale NRS and Brief Pain Inventory-short form BPI-sf, functional status through knee outcome scores, quality of sleep, opioid use, adverse events, patient satisfaction, healthcare utilization, and other health-related quality of life measures. Data collection continues for up to 18 months to observe outcomes and treatment effects over time.

All AgesAll Genders
19 locations
E

Actively Recruiting

Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.

Age: 40Years +All GendersPhase 3
977 locations

1-10 of 15

1